Indivior was under the cosh on Wednesday after US alternative asset management firm Scopia Capital sold 20m shares in the opioid addiction treatment maker in a placing.
The shares were placed at 250p each and the placing represents around 2.8% of the issued share capital.
Following completion, Scopia Capital will hold just over 96.8m shares in Indivior, which is a 13.5% stake. Scopia will retain its seat on the board “and remains a committed long-term shareholder”.
Indivior will remain Scopia’s top holding after completion.
Jefferies acted as sole global coordinator and bookrunner on the placing.
At 0805 GMT, the shares were down 4.4% at 251.40p.
